Insider Selling: BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Sells $16,803.60 in Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Troy Wichterman sold 660 shares of the firm’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $25.46, for a total transaction of $16,803.60. Following the completion of the transaction, the chief financial officer now directly owns 120,960 shares in the company, valued at $3,079,641.60. This represents a 0.54 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.

Troy Wichterman also recently made the following trade(s):

• On Wednesday, February 12th, Troy Wichterman sold 159 shares of BioLife Solutions stock. The stock was sold at an average price of $26.54, for a total transaction of $4,219.86.
• On Monday, January 6th, Troy Wichterman sold 987 shares of BioLife Solutions stock. The stock was sold at an average price of $27.02, for a total transaction of $26,668.74.

BioLife Solutions Stock Down 3.6 %

BLFS stock opened at $25.83 on Friday. The firm has a market cap of $1.21 billion, a PE ratio of -24.37 and a beta of 2.04. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78. The firm’s 50 day moving average price is $26.66 and its 200-day moving average price is $25.49. BioLife Solutions, Inc. has a one year low of $14.84 and a one year high of $29.55.

BioLife Solutions (NASDAQ:BLFS) last posted its earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.32. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. The firm had revenue of $22.71 million during the quarter, compared to the consensus estimate of $21.73 million. During the same quarter last year, the firm earned ($0.21) EPS. On average, equities research analysts anticipate that BioLife Solutions, Inc. will post -0.3 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. Craig Hallum raised their target price on shares of BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. TD Cowen raised their target price on shares of BioLife Solutions from $28.00 to $31.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Northland Securities raised their target price on shares of BioLife Solutions from $28.00 to $31.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 8th. HC Wainwright raised their target price on shares of BioLife Solutions from $27.00 to $30.00 and gave the stock a “buy” rating in a research note on Thursday. Finally, KeyCorp raised their target price on shares of BioLife Solutions from $30.00 to $33.00 and gave the stock an “overweight” rating in a research note on Friday, December 13th. One analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $29.86.

Institutional Trading of BioLife Solutions

Several institutional investors have recently added to or reduced their stakes in the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in BioLife Solutions by 13.2% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 70,686 shares of the medical equipment provider’s stock valued at $1,835,000 after purchasing an additional 8,258 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in BioLife Solutions in the 4th quarter valued at approximately $31,000. Point72 Asset Management L.P. acquired a new stake in BioLife Solutions in the 4th quarter valued at approximately $11,113,000. ProShare Advisors LLC acquired a new stake in BioLife Solutions in the 4th quarter valued at approximately $282,000. Finally, Millennium Management LLC increased its holdings in BioLife Solutions by 49.1% in the 4th quarter. Millennium Management LLC now owns 1,145,347 shares of the medical equipment provider’s stock valued at $29,733,000 after purchasing an additional 377,111 shares during the last quarter. Institutional investors and hedge funds own 93.24% of the company’s stock.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.